Condition: Atopic Dermatitis · Eczema · Sponsor: Pfizer
The purpose of this study is to learn about the safety and effects of Abrocitinib in the real-life clinical setting given for the treatment of moderate to severe atopic dermatitis. Atopic dermatitis, or AD, is a long-lasting disease that causes inflammation, redness, and irritation of the skin. This study is seeking participant who are older than 18 years with moderate-to-severe chronic AD. Participants must have no underlying medical conditions that prevent them from taking Abrocitinib. All participants in this study will receive Abrocitinib as a tablet once daily. They can take Abrocitinib and use medicated topical treatment for AD at the same time. We will examine the experiences of patients receiving the study medicine. This will help us determine if the study medicine is safe and helps in treating AD. Participants will take part in this study for 24 months. During this time, they will visit the study clinic about 5 times (about 1 time every 4 to 6 months).
This description comes directly from the study's public registry record.
Pfizer CT.gov Call Center · 1-800-718-1021 · ClinicalTrials.gov_Inquiries@pfizer.com
Always discuss trial participation with your own doctor first.
| CHU Amiens-Picardie - Site Nord | Amiens, Somme, France | Recruiting |
| CHU Besancon - Hopital Jean Minjoz | Besançon, France | Recruiting |
| Polyclinique Reims Bezannes | Bezannes, France | Recruiting |
| Chu Bordeaux Hopital Saint Andre | Bordeaux, France | Recruiting |
| CHU Brest Hopital Morvan | Brest, France | Recruiting |
| CHU de Caen | Caen, France | Recruiting |
| Ch de Calais | Calais, France | Recruiting |
| Ch William Morey | Chalon-sur-Saône, France | Recruiting |
| CHU Clermont Ferrand - Hopital Gabriel Montpied | Clermont-Ferrand, France | Recruiting |
| Chu Estaing | Clermont-Ferrand, France | Recruiting |
| Hopital Henri Mondor | Créteil, France | Recruiting |
| Chu Dijon | Dijon, France | Recruiting |
+ 18 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05689151